Additional Listing

RNS Number : 5867W

IQE PLC

12 June 2008

 



IQE plc (the 'Company')

Additional Listing

Application has been made to the London Stock Exchange for 399,566 ordinary shares of 1p each in the Company ('Ordinary Shares') to be admitted to trading on AIM. The Ordinary Shares are being issued pursuant to the exercise of share options by certain employees under the IQE Group Share Option Scheme. The Ordinary Shares are issued at the following prices:

Price of issue	Number of Ordinary Shares
Total at 5.633p	73,329
Total at 6.600p	13,440
Total at 6.670p	293,237
Total at 6.870p	19,560
TOTAL	399,566

Admission of these Ordinary Shares is expected to become effective on 18 June 2008.

Following this issue the total number of Ordinary Shares in issue will be 432,437,420.

Contacts:
IQE plc Drew Nelson Phil Rasmussen Chris Meadows	[phone]
College Hill Adrian Duffield/ Ben Way	[phone]
Noble & Company Limited John Llewellyn-Lloyd/ Sam Reynolds	[phone]
Panmure Gordon (UK) Limited Aubrey Powell/ Ashton Clanfield	[phone]

  NOTE TO EDITORS

IQE plc is the leading global supplier of advanced semiconductor wafers with products that cover a diverse range of applications. It is able to provide a 'one stop shop' for the wafer needs of the world's leading compound semiconductor manufacturers, who in turn use these wafers to make the chips which form the key components of virtually every high technology system. IQE has particular focus on the growing global wireless sector for applications including; mobile handsets, wireless infrastructure, Wi-Fi, WiMAX, base stations, GPS and satellite communications; as well as for the optical communication sector including; optical storage (CD, DVD), laser optical mice, laser printers & photocopiers, thermal imagers, leading-edge medical products, bar-coding, high efficiency LEDs and advanced solar cells.

The manufacturers of these chips are increasingly seeking to outsource wafer production to specialist foundries such as IQE in order to reduce overall wafer costs and accelerate time to market. IQE is unique in being able to supply wafers using all of the leading crystal growth technology platforms including Metal Organic Vapour Phase Epitaxy (MOVPE) and Molecular Beam Epitaxy (MBE) and the Group is able to leverage its global purchasing volumes to reduce the cost of raw materials.

IQE also provides bespoke R&D services to deliver customized materials for specific applications and offers specialist technical staff to manufacture to specification either at its own facilities or on the customer's own sites. This is backed by a strategy of duplicating each key product processes over multiple sites to assure customers of security of supply as well as provide compelling customer benefits in terms of flexibility and predictability of cost, thereby significantly reducing operating risk.

IQE operates six manufacturing facilities; two in Cardiff and one in Milton Keynes in the UK; two more in Bethlehem, Pennsylvania and Somerset, New Jersey in the USA; and its most recent acquisition in Singapore. The Group also has 11 sales offices located in major economic centres worldwide.

 

END

 

 

LISLLLFFVQBZBBF